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Abstract
Burkholderia pseudomallei is a soil-dwelling organism present throughout the tropics. It is
the causative agent of melioidosis, a disease that is believed to kill 89,000 people per year.
It is naturally resistant to many antibiotics, requiring at least two weeks of intravenous treat-
ment with ceftazidime, imipenem or meropenem followed by 6 months of orally delivered co-
trimoxazole. This places a large treatment burden on the predominantly middle-income
nations where the majority of disease occurs. We have established a high-throughput assay
for compounds that could be used as a co-therapy to potentiate the effect of ceftazidime,
using the related non-pathogenic bacterium Burkholderia thailandensis as a surrogate. Opti-
mization of the assay gave a Z’ factor of 0.68. We screened a library of 61,250 compounds
and identified 29 compounds with a pIC50 (-log10(IC50)) greater than five. Detailed investiga-
tion allowed us to down select to six “best in class” compounds, which included the licensed
drug chloroxine. Co-treatment of B. thailandensis with ceftazidime and chloroxine reduced
culturable cell numbers by two orders of magnitude over 48 hours, compared to treatment
with ceftazidime alone. Hit expansion around chloroxine was performed using commercially
available compounds. Minor modifications to the structure abolished activity, suggesting
that chloroxine likely acts against a specific target. Finally, an initial study demonstrates the
utility of chloroxine to act as a co-therapy to potentiate the effect of ceftazidime against B.
pseudomallei. This approach successfully identified potential co-therapies for a recalcitrant
Gram-negative bacterial species. Our assay could be used more widely to aid in chemother-
apy to treat infections caused by these bacteria.
Introduction
Burkholderia pseudomallei is the causative agent of melioidosis, a disease endemic to many
regions across the tropics [1]. It is believed to cause approximately 89,000 deaths per annum
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worldwide [2,3], with the large majority of the burden falling on less developed or lower mid-
dle income countries. Melioidosis can present in many ways, which significantly complicates
diagnosis [4]. Clinical presentations include skin infections, suppurative parotitis, genitouri-
nary infections, and pneumonia [5]. The most serious infections can develop to sepsis, and
abscesses on internal organs are common [1,6]. In the absence of treatment, mortality from
acute infections is high; even with treatment, mortality approaches 40% in many affected areas
[7]. Patients with access to adequate diagnostic and treatment facilities have reduced mortality
rates [8] and are treated with an intensive treatment phase of intravenously delivered ceftazi-
dime, imipenem or meropenem for at least 14 days [9–11], followed by oral eradication ther-
apy with co-trimoxazole lasting between 3 and 6 months [1,12,13]. The cost of this treatment
regime is high and the burden of disease in the least developed countries (e.g. Cambodia) may
prevent those in need from being treated [14,15]. In many lower income settings alternative
eradication regimes are used that have increased disease relapse rates [16].
B. pseudomallei is found in soil and water, preferring anthrosol and acrisol soil types [2,3].
Like many Burkholderia, it is an opportunistic pathogen of humans, and most patients have at
least one pre-disposing risk factor (with diabetes mellitus the most common) [17]. In the host,
B. pseudomallei generally adopts an intracellular lifestyle, and can invade and replicate in a
range of cell types [18]. The intracellular location also makes antibiotic chemotherapy more
challenging as compounds must cross an additional biological membrane.
B. pseudomallei is naturally resistant to many clinically used antibiotics, including some of
the more recently developed antibiotics [1,9,10,19]. When cultured to stationary phase or in
hypoxic conditions, most Burkholderia species show a high subpopulation that are recalcitrant
to antibiotic treatment [20]. This observation is believed to mimic behavior in vivo, with B.
pseudomallei surviving in biofilms or intracellular niches where cellular conditions promote
antibiotic tolerance [21–23]. This can then lead to recurrent or latent forms of the disease and
the relapse of infections in humans where longer term antibiotic treatment is not administered
[24]. Although significant progress has been made towards a melioidosis vaccine, candidates
are yet to enter clinical trials [25,26].
This presents an urgent unmet need for affordable novel drugs that supplement current
effective therapeutics to reduce the cost and duration of treatment and to prevent relapse of
infection [11,27]. We hypothesized that small molecules could act as co-therapies that could be
administered alongside front-line treatments with the aim of reducing the rates of recurrent
infection. We aimed to develop an assay that would allow rapid screening of a compound
library to identify and validate such compounds, as a step towards a potential therapy. As B.
pseudomallei is a Containment Level 3 bacterium, Burkholderia thailandensis was selected for
this study. This is a close relative of the pathogenic B. pseudomallei with over 85% gene conser-
vation [28]. As B. thailandensis does not cause disease in immunocompetent humans [28–30],
it is commonly used as a surrogate for B. pseudomallei. Previous studies have shown that
approximately 0.1% of B. thailandensis cells survive for 24 hours following treatment with
100X MIC (minimum inhibitory concentration; the lowest concentration of an antibiotic
required to prevent observable growth of the bacterium; c.f. 5–10% of B. pseudomallei survive
such treatment) of the front-line antibiotic ceftazidime in vitro [20].
A phenotypic assay using the cell viability reagent PrestoBlue™ was used to screen com-
pounds from a diversity library containing nearly 5,000 core fragments [31] at the Drug Dis-
covery Unit (DDU) in Dundee. Preliminary screening identified six compounds that were
active as co-therapies and potentiated the effect of ceftazidime against B. thailandensis. Follow-
ing hit confirmation and potency determination, we identified chloroxine, which had an IC50
(concentration at which 50% of the maximal growth inhibition is observed) value lower than
10 μM, as the most promising compound. Chloroxine was able to reduce the proportion of
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cells surviving ceftazidime treatment by at least two orders of magnitude. Evaluation of struc-
turally similar compounds suggested that chloroxine has a specific effect. This study suggests
that chloroxine has strong potential for further development as a ceftazidime co-therapy for
melioidosis.
Materials and methods
Bacterial strain and culture conditions
B. thailandensis strain E264 (ATCC; strain 700388) was grown in high salt (10 g/L) Lysogeny
broth (LB) at 37˚C with aeration at 200 rpm. For experiments investigating the activity of the
combination therapy, B. thailandensis was grown to stationary phase in LB broth and cells har-
vested by centrifugation. Cell pellets were resuspended in M9 minimal media [32] supple-
mented with 730 μM/400 μg/ml ceftazidime hydrate (Melford Laboratories, #C5920; hereafter
referred to as ceftazidime). Initial cell counts were determined from the absorbance at 600 nm.
An OD600 of 0.2 corresponds to 2x10
8 cfu (Claudia Hemsley, University of Exeter, personal
communication). For growth of B. pseudomallei strain K96243 (S. Songsivilai, Siriraj Hospital),
bacteria were plated onto low salt (5 g/L) LB-agar. Single colonies were picked into 100 ml low
salt LB broth and grown at 37˚C for 20 hours with orbital shaking. Cells were harvested by cen-
trifugation and pellets resuspended in M9 minimal media. Ceftazidime was prepared from a
stock at 73 mM active component in 0.1 M sodium hydroxide. Chloroxine (Sigma-Aldrich,
#D64600) was prepared from a stock at 10–100 mg/ml active component in dimethyl sulfoxide
(DMSO).
Cell viability assay
Detection of cell viability with PrestoBlue™ (Life Technologies, #A13261) was performed in 96
and 384 well, black walled assay plates (Corning, #3904 and #3573 respectively) by adding 10%
PrestoBlue (v/v) to each bacterial culture. Following the addition of PrestoBlue, plates were
incubated at room temperature for one hour and fluorescence was read at ex 540/em 590 nm
by an Envision plate reader (PerkinElmer), or an Infinite M200 Pro (Tecan). All liquid han-
dling in the primary screen and hit expansion was automated.
An assay was developed to discriminate two-fold changes in cell numbers. A bacterial cul-
ture was prepared as described above and serially diluted in an equal volume of M9 media to
produce two-fold dilutions. A positive control (cells resuspended in M9 media without ceftazi-
dime) and a negative control (cells heat killed at 90˚C for 2 minutes) were included in these
assays. Plates were incubated at 37˚C overnight before addition of PrestoBlue reagent and the
reading of fluorescence as described previously.
High throughput screening
A library of 61,250 compounds was prepared as stock solutions in DMSO at a concentration of
10 mM and supplied in 384-well Echo plates (Labcyte, #P-05525) for use in this screen. 45 μl of
a culture resuspended in M9 media supplemented with 730 μM ceftazidime to an OD600 nm of
0.8 (equivalent to late log phase growth, equivalent to 8x108 cfu/mL) was added to give a final
compound concentration of 30 μM. Plates were covered with AeraSeal film (Sigma-Aldrich,
#A9224) before incubation for 24 hours at 28˚C. A single point (SP) screen of all compounds
was performed.
309 compounds from the diversity library were tested for potency using a standard ten
point half logarithm concentration response protocol [33]. Selected hits were dispensed into
384 well Echo plates using a Biomek FX automated liquid handling workstation (Beckman
PLOS ONE Compounds co-therapies for the treatment of Burkholderia species
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Coulter); two-fold serial dilutions of each compound in DMSO was performed using an Echo
550 liquid handler (Labcyte).
Our specifications for assay design stipulated a Z factor> 0.5 [34,35].




Where μp and σp are the mean and standard deviation of cells treated with ceftazidime,
and μn and σn are the mean and standard deviation of the negative controls. A worked exam-
ple calculation is available in the legend to S1 Fig.
Data processing and analysis
Data analysis was performed within ActivityBase (IDBS) and report creation was undertaken
using Vortex (Dotmatics). All IC50 curve fitting was undertaken within Activity Base XE utiliz-
ing the underlying ‘MATH IQ’ engine of XLfit version 5.1.0.0 from IDBS. Curve fitting was







where A = % inhibition at bottom, B = % inhibition at top, C = 50% effect concentration
(IC50), D = slope, x = inhibitor concentration and y = % inhibition. As IC50 values are Log nor-
mally distributed, fitted IC50 values are stated as the pIC50 (-log10[IC50]).
Minimum inhibitory concentration (MIC)
These were determined following the CLSI recommended protocol for antimicrobial suscepti-
bility testing via micro dilution method [36,37]. Experiments were initiated with an inoculum
of approximately 1 x105 cfu of B. thailandensis, and evaluated a concentration range from 0–-
1000 μM. Growth was detected by absorbance at 600 nm using an Infinity M200 Pro plate
reader (Tecan). Synergistic interactions of chloroxine and ceftazidime were tested by mixing
equal volumes of media prepared using the micro dilution method, to test concentrations of
each antibiotic from 0–32 μg/ml. Samples were then treated as above.
IC50 determination
90 μL of a culture prepared as above and resuspended in M9 media supplemented with
730 μM ceftazidime to an OD600 nm of 0.8 was treated with two-fold dilutions of compounds
in DMSO (in a final DMSO concentration of 0.016% (v/v)). Samples were incubated in a 96
well black walled plate covered with AeraSeal film (SigmaAldrich) at 28˚C for 24 hours before
quantification of viable cells with PrestoBlue as above. IC50 values were fitted to Eq (2) using
Graphpad Prism version 6.0.1.
Time dependent killing
A stationary phase culture of B. thailandensis was centrifuged and resuspended in 10 ml LB to
an OD600 nm of 0.4 (equivalent to 4 x10
8 cfu/mL). Samples were treated with 730 μM ceftazi-
dime hydrate, 30 μM chloroxine in DMSO, or both. Samples were incubated at 37˚C with
shaking. 1 mL samples were taken at time intervals over a 48 hour period (0, 4, 8, 24, 48 hr),
cells harvested and resuspended in LB before serial dilution and plating on agar. Colonies were
counted following 24 hours incubation at 37˚C. All samples contained DMSO at 0.083% (v/v).
PLOS ONE Compounds co-therapies for the treatment of Burkholderia species
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Results
Assay development
The aim of this study was to identify compounds that may have use as co-therapies for the
treatment of infection with B. pseudomallei. We aimed to develop an assay that would identify
compounds that reduced the proportion of B. thailandensis cells that remained viable when
delivered in combination with ceftazidime (730 μM; 400 μg/ml; this is equivalent to the peak
blood concentration given for melioidosis septicemia; c.f. MIC of 2–6 μg/ml for common B.
pseudomallei isolates [38–40]). We evaluated the effectiveness of our assays using the Z’ statis-
tic [34], commonly used for high-throughput screening (HTS) [41]. The requirement of this
initial assay was to distinguish a ceftazidime treated culture from heat killed cells (negative
control) with a Z’ score greater than 0.4. We investigated a range of absorbance, fluorescence,
luminescence, and qPCR-based assays for correlates of cell viability (S1 File). A phenotypic cell
viability assay using the resazurin-based reagent PrestoBlue met our criterion, showing a
greater Z’ score than the alternative assays (Fig 1). This cell viability assay offered high
throughput screening that was convenient and affordable, with good discrimination in the
reduction of surviving B. thailandensis cells. The assay conditions (incubation temperature,
volume, and sealing) were then optimized for use in 384 well plates with automated dispensing
of reagents. The final assay quality was determined, comparing B. thailandensis at the opti-
mized cell density in M9 media supplemented with ceftazidime, to media without bacteria.
The final assay resulted in a Z’ score of 0.68 (S1 Fig), which is consistent with the HTS require-
ment for a score of 0.5–0.7. Assay quality was maintained throughout the HTS.
High throughput screening. Primary single point screening took place for the 61,250
compounds comprising the DDU’s Diversity screening library [31]. As expected, the majority
of the compounds were inactive (Fig 2), with some compounds showing compound effects on
the assay (indicated by the tail of compounds showing >150% of the mean fluorescence).
Using the median percentage effect plus three standard deviations, a cut-off of 34.3% inhibi-
tion was determined. This identified 2,127 unique compounds as ‘hits’, which exceeded the
capability for downstream analysis. As a result, a pragmatic cut off of 45% inhibition was
selected (Fig 2, red arrow), resulting in 345 unique compounds. Some of these were excluded
due to known promiscuity issues. We selected 309 compounds for detailed screening: these
included some near analogues to hits from within the DDU collection that showed good activ-
ity and physiochemical properties. For these 309 compounds, a ten point, 2-fold, concentra-
tion response assay was performed in duplicate (S2 Fig) with criteria for a positive hit set at
greater than 50% inhibition at the highest concentration tested (100 μM). Acceptable concen-
tration response relationships were returned for 58 compounds, of which 29 showed a pIC50
(-log10(IC50)) values > 5, indicating 50% activity at 10 μM and a potential “hit”.
Down selecting compounds. Concentration dependent killing assays were repeated for the
29 compounds selected using newly sourced stocks of the same compounds and performed in
triplicate over a larger range of concentrations. pIC50, hillslope and maximal effect were used
to further down select to six compounds (A-F), all of which displayed a pIC50 > 5 in either the
primary assay (Fig 3A, Table 1), the secondary assay (S3 Fig, S1 Table) or both. One of these
compounds (compound A, 5,7-dichloroquinolin-8-ol, also known as chloroxine; Fig 3B), is a
currently licensed antimicrobial. Our further investigations focused on chloroxine.
Minimum inhibitory concentration (MIC). The experiments described above highlighted
that chloroxine had activity on cells that had survived following ceftazidime treatment. Our
hypothesis was that chloroxine either potentiated the effects of ceftazidime or was toxic to cells
in a metabolic state that rendered them insensitive to ceftazidime. We reasoned chloroxine
might be acting as an antibiotic in its own right, as so determined its MIC. Chloroxine
PLOS ONE Compounds co-therapies for the treatment of Burkholderia species
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demonstrated antimicrobial activity, with an MIC of 4 μg/mL (compared with 4–8 μg/mL for
ceftazidime). This was not unexpected, as chloroxine is known to be an effective antimicrobial
with activity described against a range of Gram-positive bacteria and fungi. Chloroxine and
ceftazidime showed no evidence of synergistic effects on MIC (S4 Fig), suggesting that the
effects observed reflected the potentiation of the ceftazidime effect on tolerant cells.
Time dependent killing. A time dependent killing assay was performed to demonstrate that
the effect of chloroxine was complementary to ceftazidime. Stationary phase cells were resus-
pended in fresh media supplemented with ceftazidime (100X MIC), with or without 30 μM of
chloroxine. Bacterial counts were determined over 48 hours of incubation. Chloroxine
Fig 1. The PrestoBlue assay shows discrimination between the numbers of surviving cells. A B. thailandensis culture was harvested, resuspended, and diluted in M9
media supplemented with 730 μM ceftazidime, to provide a series of cell densities at two-fold intervals. Samples were incubated statically at 28˚C in 96 well plates.
PrestoBlue was added following 20 hours of incubation and the fluorescence read gain optimized for the highest bacterial concentration. The results show reliable
discrimination of two-fold differences in cell numbers when compared to a heat killed cell negative control. � All show Z’> 0.5 when compared to the controls. Positive
control: Cells resuspended in M9 media without ceftazidime. Data shows biological triplicates, whiskers indicate the minimum and maximum results, the box the 25th to
75th percentiles and the central line indicates the median.
https://doi.org/10.1371/journal.pone.0248119.g001
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Fig 2. Inhibitory activity of test compounds screened with a phenotypic assay. A B. thailandensis culture was harvested and
resuspended in M9 media supplemented with 730 μM ceftazidime and 30 μM of each of the compounds. Cells were grown at
28˚C for 20 h, and PrestoBlue added. Inhibition was calculated by comparisons to the controls. The distribution shows the
percentage inhibition grouped in 5% windows for the HTS of 61,250 compounds. The median activity is 5.3%. The standard
deviation of the positive tail is 9.65%, giving a statistical cut-off for activity of 34.3%. The red arrow indicates the selected
pragmatic threshold at 45%. 345 compounds were identified as ‘hits’ according to this criterion.
https://doi.org/10.1371/journal.pone.0248119.g002
Fig 3. pIC50 determination of six candidate compounds using the PrestoBlue cell viability assay. A: A B. thailandensis culture was harvested and resuspended to a
concentration of 8x108 CFU/mL in M9 media supplemented with 730 μM ceftazidime. This was added to a 96 well plate containing two-fold dilutions of compounds in
DMSO from 500 μM. Plates were incubated for 24 hours at 37˚C before the addition of the PrestoBlue cell viability reagent and the fluorescence read. Results show three
biological replicates with error bars indicating standard error. The derived IC50 values are detailed in Table 1. B: Structure of chloroxine.
https://doi.org/10.1371/journal.pone.0248119.g003
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significantly reduced the number of viable cells following incubation for 24 hours when com-
pared to treatment with ceftazidime or chloroxine (p< 0.05, and p< 0.005 respectively), with
a reduction in cell number by nearly two orders of magnitude at 48 hours (Fig 4). This vali-
dated the antimicrobial activity of chloroxine. We also performed a cytotoxicity assay that
demonstrated that chloroxine was not toxic to mammalian cells (S5 Fig).
Hit expansion. One possibility was that chloroxine was acting non-specifically as an oxidiz-
ing agent. Hit expansion using similar commercially available compounds was performed to
gain insight into the structure-activity relationship. This would also assist in the future devel-
opment of this compound from hit to lead.
Chloroxine (Fig 3B) is a small synthetic compound with limited scope for improvement.
The pIC50 was determined as 5.5 using the PrestoBlue assay (Fig 3A). A total of eleven similar
compounds were commercially available and were used for this screen. None of these demon-
strated increased potency in the assay (Fig 5). However, the pattern of loss of potency provides
clear insights into how chloroxine could be further modified. It was clear that the identity of
the substituent at the 7-position was important. Replacement of this with an amino group sig-
nificantly reduced activity (pIC50 reducing to 3.4; Fig 5A). Similarly, addition of a methyl
group at the 2-position was poorly tolerated, leading to a loss of detectable activity at the con-
centrations tested (Fig 5B). The halogens in the compound could also be altered to some
extent. Replacement of the chlorine atom with bromine at the 7-position was tolerated, but
only if the chlorine in the 5-position was also removed (reduction in pIC50 from 5.5 to 5.1, Fig
5C). Two alternative structures with bromine were not active (S2 Table). Iodide ions were also
tolerated in place of the chlorines, again with a small loss of activity (S2 Table). More extensive
alterations to the structure of chloroxine resulted in the loss of at least one order of magnitude
of activity (S2 Table).
Finally, to validate the use of B. thailandensis as a proxy for B. pseudomallei, we repeated the
original PrestoBlue assay with ceftazidime and chloroxine against B. pseudomallei. The fluores-
cent signal seen for B. pseudomallei was approximately double the B. thailandensis signal; this
is unlikely to be significant as the level of fluorescence is known to vary between species with
this reagent [42]. Chloroxine demonstrated a similar level of activity against B. pseudomallei to
that seen against B. thailandensis (Fig 6; IC50 for B. thailandensis 2.0 μM (95% CIs 1.7–
2.2 μM); IC50 for B. pseudomallei 9.2 μM (95% CIs 7.2 to 12 μM). This result suggests that our
assay could be used with B. pseudomallei.
Discussion
This study aimed to identify compounds that were effective in reducing the proportion of Bur-
kholderia cells that survive following treatment with ceftazidime at concentrations much
higher than the MIC. Ceftazidime is a front-line therapy for the acute phase of the disease
melioidosis [1]. Ceftazidime specifically targets penicillin-binding protein 3 in B. pseudomallei
Table 1. Analysis of the concentration dependent killing data shown in Fig 3.
Compound Top/RFU Bottom/RFU Hill Slope pIC50 (IC50 in M) R Square Number of Points Analysed
A 37600 10700 1.7 5.5 0.98 42
B 33400 11900 3.8 4.6 0.95 45
C 48000 25500 1.1 7.2 0.96 48
D 32000 36000 0.7 4.6 0.22 48
E 25000 37200 1.5 5.2 0.75 48
F 12000 29000 2.2 5.1 0.72 48
https://doi.org/10.1371/journal.pone.0248119.t001
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Fig 4. A secondary assay evaluating the number of culturable cells remaining following treatment with ceftazidime and chloroxine. A
culture of B. thailandensis was treated with 730 μM ceftazidime hydrate, 30 μM chloroxine, both, or neither. Samples were incubated at 37˚C
with shaking. Samples were taken at time intervals, cells harvested and resuspended in LB broth before serial dilution and enumerating on agar.
Error indicates standard error of serial dilution and CFU count. n = 6. Differences between the ceftazidime alone, chloroxine alone, and
ceftazidime and chloroxine samples were analyzed using a Kruskal-Wallis test with Dunn post-hoc comparison using Graphpad v. 7.03. �—
p< 0.01 between chloroxine alone, and ceftazidime with chloroxine. ��—p< 0.05 between both chloroxine alone and ceftazidime alone, and
both compounds.
https://doi.org/10.1371/journal.pone.0248119.g004
PLOS ONE Compounds co-therapies for the treatment of Burkholderia species
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[23,43]; the B. thailandensis orthologue shows 97% identity at the amino acid level. Ceftazi-
dime treatment at sub-MIC concentrations induces filamentation of B. pseudomallei, whilst
ceftazidime is lytic at higher concentrations [44]. Our study aimed to identify compounds that
could be developed to be administered alongside front-line treatments, with the aim of reduc-
ing the rates of recurrent infection. This may then allow the duration and cost of the treatment
to be reduced.
We decided that the use of a whole cell, phenotypic assay was advantageous for this applica-
tion. Cells in the low metabolic state that provide resistance to antibiotics such as ceftazidime
are heterogeneous [45], and cover a range of phenotypes. As such, a phenotypic assay focusing
Fig 5. Hit expansion around chloroxine. A B. thailandensis culture was harvested and resuspended to a concentration of 8x108
CFU/mL in M9 media supplemented with 730 μM ceftazidime. This was added to a 96 well plate containing two-fold dilutions of
compounds in DMSO from a starting concentration of 1 mM. Plates were incubated for 24 hours at 37˚C before addition of the
PrestoBlue cell viability reagent and the fluorescence read. Results show three biological replicates with error bars indicating
standard deviation. These experiments are equivalent to those in Fig 3 and can be compared to chloroxine in Fig 3. 7-amino-
5-chloro-8-quinolinol differs to chloroxine through substitution of an amino group for a chlorine at position 7 (A). This
modification causes a significant decrease in this compound’s activity as a co-treatment with ceftazidime, with a pIC50� 3.4.
5,7-dichloro-2-methyl-8-quinolinol differs from chloroxine by addition of a methyl group in the 2-position (B). This addition
abolishes this compound’s activity as a co-treatment with ceftazidime at the concentrations tested. 7-Bromo-8-quinolinol differs
from chloroxine by the removal of chlorine at the 5-position, and replacement of chlorine by bromine at the 7-position (C). This
compound retains activity as a co-treatment with ceftazidime that is comparable with the parent compound (pIC50 = 5.1, 5.5 for
chloroxine).
https://doi.org/10.1371/journal.pone.0248119.g005
Fig 6. pIC50 determination using the PrestoBlue cell viability assay to compare the concentration dependent killing for ceftazidime used in combination with
chloroxine to treat B. thailandensis and B. pseudomallei. B. thailandensis and B. pseudomallei cultures were harvested and resuspended to a concentration of 8x108
CFU/mL in M9 media supplemented with 730 μM ceftazidime. These were added to a 96 well plate containing two-fold dilutions of chloroxine in DMSO. Plates were
incubated for 24 hours at 37˚C before the addition of the PrestoBlue cell viability reagent and determination of fluorescence. Results show three biological replicates with
error bars indicating standard deviation. pIC50 for B. thailandensis = 5.7; pIC50 for B. pseudomallei = 5.0.
https://doi.org/10.1371/journal.pone.0248119.g006
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on the reductive state of the cell was preferred over a target-based assay for identifying tracta-
ble hit compounds. In addition, phenotypic screening is regaining popularity over target-
based screening. The principal reasons for this are that compounds with the physiological abil-
ity to penetrate Gram-negative cells, function in vivo and avoid efflux pumps are identified
[46,47]. Consequently, the compound series obtained are likely to have significant advantages
for downstream optimization and development. The use of cell viability reagents, allowing the
assessment of cells at a population or individual level, offered the opportunity to identify viable
cells in a variety of states, and was considered more relevant for this work. Resazurin based
assays have previously been shown to identify all viable cells, and not just the less abundant
“persister” cells [48]. Other phenotypic assays that have identified co-therapies against other
organisms have exploited colony counting [49,50], DNA binding dyes [51] and Live/Dead
reagents [52]. The PrestoBlue resazurin-based assay proved effective, in Burkholderia, at iden-
tifying compounds that were active at concentrations below 10 μM, validating the approach.
Primary screening with the DDU’s diversity library identified 2,127 compounds that showed a
significant effect as a co-therapy with ceftazidime, based on an activity threshold of 34.3% inhi-
bition. The preliminary hit rate was 3.5%, which is in the expected range for an effective assay.
Chloroxine was identified as a potential co-therapy to treat infection with B. thailandensis.
This compound demonstrated strong activity in the primary assay (IC50 = 2 μM) and resulted
in a significant reduction in the number of culturable bacterial cells following 24–48 hours
treatment, in combination with ceftazidime (>100-fold reduction). This is similar to the level
of efficacy that has been previously observed with compounds targeting E. coli [51]. It is
hypothesized that chloroxine would reduce the proportion of cells surviving ceftazidime treat-
ment, and so reduce the intensive treatment phase in patients with melioidosis. Chloroxine
has known bacteriostatic, fungistatic and antiprotozoal properties [53] and has previously
been shown to have synergistic effects with minocycline against Pseudomonas aeruginosa [54].
Consistent with this, administration of chloroxine alongside the frontline treatment for melioi-
dosis, ceftazidime, demonstrated improved activity than the compounds evaluated as sole ther-
apies. This suggests that the compounds have complementary effects when treating B.
thailandensis. Bactericidal effects were observed at concentrations below the chloroxine MIC
(Figs 3A and S4). This study demonstrates evidence for the concept of use of chloroxine as a
complementary agent to ceftazidime against B. thailandensis.
Hit expansion was carried out for chloroxine. Only a limited range of compounds around
the chloroxine structure were available. None of the compounds evaluated demonstrated
improved activity compared to the parent compound (S2 Table). However, it became evident
that only limited substitutions at the chlorine positions were tolerated, only compounds with
other halides in these positions showed comparable activity to chloroxine. Furthermore, addi-
tion of a methyl group in the 2-position was sufficient to abolish activity at the concentrations
evaluated (Fig 5). These data strongly suggest that chloroxine has some specificity, and it is not
a consequence of its suggested oxidative activity. The addition of a methyl group would not be
expected to reduce the oxidative capability of chloroxine, yet this abolishes activity. Further-
more, the iodo-equivalent of chloroxine retains similar activity to chloroxine and is consider-
ably less oxidizing. This hit expansion validates the hypothesis that chloroxine acts specifically
to potentiate the effect of ceftazidime.
B. thailandensis was used in the preliminary experiments as a surrogate for B. pseudomallei.
Evaluation of chloroxine against B. pseudomallei showed that chloroxine is effective as a co-
therapy for ceftazidime at druggable concentrations (Fig 6). Although activity is reduced com-
pared to that observed against B. thailandensis, these results validate the use of B. thailandensis
as a surrogate in this study. In the context of ongoing treatment for cutaneous melioidosis,
chloroxine is currently licensed for topical treatment of skin infections. It may become a useful
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addition to the existing portfolio of treatments for cutaneous melioidosis due to its low cost
and activity against B. pseudomallei. Determining the efficacy against a wider range of strains
of B. pseudomallei would provide further confidence to this proposed use. Development of co-
therapies suitable for systemic treatment would require significant chemical modification to
optimize activity and bioavailability. Chloroxine is soluble to 644 μM in water, and the peak
ceftazidime concentration in serum is 130 μM [55]. Furthermore, B. pseudomallei invades and
multiplies in phagocytic cells [56], so modification for penetration of these cells would be nec-
essary. A wider range of starting lead scaffolds would likely be necessary for such optimization.
Conclusions
Our study has demonstrated that a phenotypic assay can identify compounds that act as co-
therapies for frontline antibiotics in Burkholderia. A high throughput screen of 61,250 com-
pounds identified six compounds that demonstrated activity at concentrations of less than
10 μM. One of these compounds, 5,7-dichloro-8-quinolinol (chloroxine), is currently licensed
for other indications. Although hit expansion with commercially available compounds did not
identify any neighbors with improved activity, chloroxine significantly reduced the number of
surviving cells over 48 hours. Our data suggest that similar approaches could be highly effica-
cious in identifying useful compounds for use with other bacteria with similar clinical
challenges.
Supporting information
S1 Fig. A checkboard of microbial culture to show positional plate effects. A B. thailanden-
sis culture was harvested and resuspended to a concentration of 8x108 CFU/mL in M9 media
supplemented with 730 μM ceftazidime. 45 μl of this suspension (green) and a heat killed con-
trol (red) were added to each well in quarters of a 384 well plate. Samples were incubated stati-
cally at 28˚C. After 20 hours, PrestoBlue was added and the fluorescence read. Intensity of
colour indicates the signal strength. Maximum signal variance was 11.2%CV, with Z’ = 0.68
(Calculation: Mean of positive wells = 204,371, SD = 15,179; mean of negative wells = 37,339,
SD = 2,532). Relative fluorescence units (RFU) are given for all wells showing significantly
decreased fluorescence in edge and corner wells compared to central wells (p = 0.011). Calcula-
tion of derived Z (as a worked example of all such calculations in the manuscript):
Positive wells: Mean (μp) = 204371, standard deviation (σp) = 15179.
Negative wells: Mean (μn) = 37339, standard deviation (σn) = 2532.
Difference of means: μp—μn = 204371–37339 = 167032.
Sum of standard deviations: σp + σn = 15179 + 2532 = 17711.
Z Factor ¼ 1  
3ðσpþ σnÞ
jmp   mnj




S2 Fig. A B. thailandensis culture was harvested and resuspended to a concentration of
8x108 CFU/mL in M9 media supplemented with 730 μM ceftazidime. This was added to a
96 well plate containing a concentration response assay performed in duplicate two-fold dilu-
tions of compounds in DMSO. Plates were incubated for 24 hours at 37˚C before addition of
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PrestoBlue and the fluorescence read. The criterion for a positive hit was set as greater than
50% inhibition at the highest concentration tested (100 μM).
(TIFF)
S3 Fig. pIC50 determination from compounds B-F using SYTO9. The Live/Dead reagent
SYTO9 was used to quantify viability as a function of the membrane integrity of the cell. A B.
thailandensis culture was harvested and resuspended to a concentration of 8x108 CFU/mL in
M9 media supplemented with 730 μM ceftazidime. This was added to a 96 well plate contain-
ing two-fold dilutions of compounds in DMSO. Plates were incubated for 24 hours at 37˚C
before addition of the Live/Dead cell viability reagents and the fluorescence read. Results show
three biological replicates with error bars indicating standard error. The derived IC50 values
are shown in S1 Table.
(TIFF)
S4 Fig. Synergistic effect study. A B. thailandensis culture was diluted to an OD600 of 0.004 in
Muller-Hinton broth (MHB; Sigma). Solutions of ceftazidime and chloroxine at 4X final con-
centration in MHB were prepared by serial dilution from a master stock. Stocks were mixed
one part chloroxine stock, one part ceftazidime stock, and two parts B. thailandensis culture
(giving an inoculum of ~5 x 105 cfu) in a 96 well plate. Samples were sealed and grown at 37˚C
statically for 20 hr, following which absorbance at 600 nm was read using a plate reader. Values
were corrected for non-inoculated controls. Wells that showed growth (OD600 > 0.1, corre-
sponding with the results of visual inspection; no antibiotic controls showed an OD600 of
0.88 ± 0.1, n = 8) are highlighted in red. The plate reader results were in correspondence with
visual inspection.
(TIFF)
S5 Fig. Chloroxine does not show cytotoxic effects. Chloroxine was tested to determine
whether it had any cytotoxicity against mammalian cells. Neuroblastoma cells were selected as
a representative mammalian cell line that is robust and unaffected by DMSO at concentrations
up to 1% (v/v). Cells were plated at 20,000 cells/well in 100 μl Dulbecco’s media. 300 μM chlor-
oxine in 0.5% (v/v) DMSO, or 0.5% (v/v) DMSO (carrier) was added, and the plate incubated
for 4 or 24 hours. Cytotoxicity was determined using an LDH cytotoxicity assay kit (Thermo
Scientific #88953). Briefly, 10 μl of lysis solution (to indicate 100% lysis) or water (control) was
added to untreated wells, and these incubated at 37˚C for 45 min. 50 μl of supernatant from
each well was added to 50 μl of room temperature assay solution in a 96 well plate (Greiner
Bio-One #655201). Samples were incubated at room temperature in the dark for 30 min, and
50 μl of assay stop solution added. Absorbance at 490 nm and 680 nm was read in a M200 Pro
plate reader (Tecan), with the difference between these representing LDH activity. % cytotox-
icity was determined on a linear scale between the measurements for 100% lysis and water
only control. No significant difference was observed between treated and control cells (two-
way ANOVA testing for effect of compound or time gives p> 0.5 for each effect). n = 6; image
shows means with error bars showing SEM.
(TIFF)
S1 Table. Activities of the six most promising compounds. The structures, derived IC50 val-
ues from the resazurin and SYTO9 based assays and the MIC values are provided for each
compound. 95% confidence intervals are shown in parenthesis. IC50 values and confidence
intervals were calculated using Graphpad v. 8.3. MIC values were determined as the lowest
concentration not showing significant growth.
(DOCX)
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S2 Table. Hit expansion structures and activity for chloroxine. Each compound was tested
using the PrestoBlue assay. A B. thailandensis culture was harvested, and resuspended to a con-
centration of 8x108 CFU/mL in M9 media supplemented with 730 μM ceftazidime. This was
added to a 96 well plate containing two-fold dilutions of compounds in DMSO. Plates were
incubated for 24 hours at 37˚C before the addition of PrestoBlue and the fluorescence read.
Results show three biological replicates with error bars indicating standard deviation. All mod-
ifications resulted in reduced activity when compared to chloroxine. In cases where the data
did not fit to the model used (where no activity is demonstrated at the concentrations used),
pIC50 is recorded as N/A.
(DOCX)
S1 File. Supplementary results. A series of approaches were trialed to identify an effective
assay for determining the level of B. thailandensis cells surviving following 24 hours of expo-
sure to 730 μM ceftazidime. The PrestoBlue approach that was eventually selected is described
in detail in the main paper. The criteria used for selection was the ability to identify a four-fold
difference in initial cell numbers with clear statistical significance; affordability of reagents for
over 60,000 test samples; and ease of use in a high throughput setting.
(PDF)
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